source
- #CTAD26: Priavoid’s amyloid-detangling pill PRI-002 fails Phase 2 study in Alzheimer’sBOSTON — For nearly a decade, the German biotech startup Priavoid has been working on a pill to break up small clumps of amyloid proteins that accumulate in the brains of people with Alzheimer’s di…Endpoints · 1h ago↗ source
- Lilly pens another deal, inking up to $5.9B oncology pact with StippleA licensing pact with Stipple Bio was one of two announced by Eli Lilly on Monday, after the up to $1.5 billion buyout of blood cancer-focused Calytrix Bio.BioSpace · 2h ago↗ source
- Kyntra axes mid-stage ADC, adding to years of stumblesBeleaguered Kyntra Bio can’t catch a break. Formerly known as FibroGen, the company has endured a series of woes over the last few years, and now the biotech is cutting a clinical antibody-drug con…